erlotinib hydrochloride has been researched along with cadaverine in 1 studies
| Studies (erlotinib hydrochloride) | Trials (erlotinib hydrochloride) | Recent Studies (post-2010) (erlotinib hydrochloride) | Studies (cadaverine) | Trials (cadaverine) | Recent Studies (post-2010) (cadaverine) |
|---|---|---|---|---|---|
| 4,353 | 786 | 3,033 | 1,276 | 3 | 341 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Li, H; Shi, C; Sui, H; Yan, Z | 1 |
1 other study(ies) available for erlotinib hydrochloride and cadaverine
| Article | Year |
|---|---|
Combination of erlotinib and a PARP inhibitor inhibits growth of A2780 tumor xenografts due to increased autophagy.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Autophagy; BRCA1 Protein; BRCA2 Protein; Cadaverine; Cell Line, Tumor; ErbB Receptors; Erlotinib Hydrochloride; Extracellular Signal-Regulated MAP Kinases; Female; Humans; Mice, Inbred BALB C; Mice, Nude; Molecular Targeted Therapy; Ovarian Neoplasms; Phosphorylation; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Signal Transduction; Time Factors; Transfection; Tumor Burden; Xenograft Model Antitumor Assays | 2015 |